



Antibody-Mediated Thrombotic Diseases

Guest Editors:

Prof. Dr. Tamam Bakchoul

1. Institute for Clinical and Experimental Transfusion Medicine (IKET), University Hospital of Tuebingen, Tuebingen, Germany
2. Centre for Clinical Transfusion Medicine, University Hospital of Tuebingen, Tuebingen, Germany

Dr. Günalp Uzun

Centre for Clinical Transfusion Medicine, University Hospital of Tuebingen, 72076 Tuebingen, Germany

Deadline for manuscript submissions:

closed (10 July 2024)

Message from the Guest Editors

Dear colleagues,

In recent years, our knowledge of the interplay between adaptive immunity and hemostasis has increased considerably. One aspect of this connection is the antibody-mediated activation of the coagulation system. Antibody-mediated thrombotic diseases include thrombotic thrombocytopenic purpura (TTP), heparin-induced thrombocytopenia (HIT), and antiphospholipid syndrome (APS). Antibody-mediated platelet activation also plays a role in COVID-19-induced coagulopathy, in which thrombotic complications are an important prognostic factor. Recently, vaccine-induced immune thrombotic thrombocytopenia (MITT) was added to this list of conditions with antibody-mediated thrombosis. Platelet count and thrombosis are important clinical signs. It is critical to identify the cause responsible for thrombocytopenia, but this often proves difficult due to the complex comorbidities.

This Special Issue aims to show the latest achievements in the field of antibody-mediated thrombotic diseases, including, but not restricted to, clinical presentations, pathophysiological studies, current treatment progress, and future therapeutic perspectives.





an Open Access Journal by MDPI

Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department,
University Hospital Strasbourg,
67081 Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and
Critical Care Medicine, The
University of Tokyo, Tokyo, Japan

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's (JCM)* staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Contact Us

Journal of Clinical Medicine Editorial
Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jcm
jcm@mdpi.com
[X@JCM_MDPI](https://twitter.com/JCM_MDPI)